Regeneron's Remarkable Q3: A Dupixent-Driven Triumph That Reaffirms Biotech's Pulse
Regeneron's Growth Horizon: Beyond the Core, Towards New Frontiers
A New Chapter for Ophthalmology: Regeneron and Sandoz Resolve Landmark Eylea Patent Battle